A healthier gut may be key to cancer care
A Healthier Gut May Be Key to Cancer Care
A healthier gut may be key – In the early 1990s, Dr. Marcel van den Brink, a specialist in bloodborne cancers such as leukemia, encountered a critical challenge in his work: how to safely rebuild a patient’s immune system after intensive treatments. This delicate balancing act became the focus of a groundbreaking procedure known as allogenic hematopoietic cell transplantation, where chemotherapy was used to eliminate the patient’s existing immune cells, paving the way for donor-derived cells to take over. While this method offered hope for recovery, it also left patients highly susceptible to infections and other complications during the vulnerable period before the new immune system stabilized.
At the time, transplant patients were often isolated in controlled environments, sometimes referred to as “bubbles,” to minimize exposure to harmful pathogens. Van den Brink recalled how nurses and families had to wear gloves to interact with patients through plastic barriers, emphasizing the extreme precautions taken to maintain sterility. Patients were also administered high-dose antibiotics to prevent bacterial infections, but even these measures couldn’t fully eliminate the risk. In the 1990s, roughly a quarter of patients still succumbed to infections or graft-versus-host disease, where donor immune cells attacked the recipient’s tissues. This realization sparked a paradigm shift in cancer research, linking the body’s gut microbiome to its immune function.
“We were causing a lot of collateral damage with our aggressive treatment,” said van den Brink, reflecting on how the medical community’s focus on eliminating all microbes left patients with unintended consequences.
Recent advancements have illuminated the gut microbiome’s vital role in immunity, leading to a surge of studies exploring its potential in cancer therapy. This field gained renewed attention when U.S. Health and Human Services Secretary Robert F. Kennedy Jr. attended a research symposium at the City of Hope Cancer Center in Duarte, California. There, Dr. Jay Bhattacharya, director of the National Institutes of Health, hailed the findings as “mind-blowing,” underscoring the microbiome’s status as “the next frontier of cancer prevention and care.” The event highlighted the growing consensus that gut bacteria could be a cornerstone of treatment strategies.
The Microbiome’s Influence on Immunotherapy
Immunotherapy, which harnesses the body’s own immune system to fight cancer, has become increasingly reliant on the gut microbiome’s support. Researchers now believe that specific microbial communities can enhance the effectiveness of therapies, such as checkpoint inhibitors, by modulating immune responses. This idea has led to a wave of clinical trials aiming to manipulate the microbiome to improve patient outcomes. One such trial, conducted at the University Hospitals Seidman Cancer Center in Cleveland, marks a significant step forward by testing probiotics in a late-phase study.
The trial involves a strain of bacteria called Clostridium butyricum, branded as CBM588. This probiotic, already popular in Japan as an over-the-counter supplement for digestive issues, is being evaluated for its ability to amplify cancer treatment responses. Nearly 700 individuals with advanced renal cell carcinoma will participate, receiving CBM588 alongside their standard immunotherapy regimens. Dr. Pedro Barata, one of the principal investigators, expressed optimism about the study’s goals, stating, “We’re hoping to change the standard of care.” The National Cancer Institute is funding the research, which builds on earlier smaller-scale studies, including one from City of Hope Cancer Center in Los Angeles that found CBM588 improved outcomes for patients with kidney cancer.
A Decade of Insight from Poultry Operations
The connection between gut bacteria and health has roots in unexpected places. Dr. Sumanta Pal, who co-led the City of Hope study, traced his interest in the microbiome to a conversation over a decade ago with Dr. Paul Frankel, a biostatistician at the center. Frankel shared observations from poultry farms, where producers noticed that chickens with robust gut bacteria tended to thrive without frequent litter cleaning. “If their chickens are [healthy and growing well], they’ll limit how often they clean the litter when they put in new chickens,” Frankel explained. This insight revealed how microbial balance could influence disease resistance, a concept that later resonated in human medicine.
Pal expanded on this idea, noting that livestock farmers often use probiotics or prebiotics to support gut microbiota. For instance, pigs are routinely fed inulin, a dietary fiber that acts as a prebiotic to promote the growth of Bifidobacteria. These real-world applications laid the groundwork for understanding how microbes might shape immune health in humans. “It’s basically a fiber product that is a prebiotic, and they use that to boost the Bifidobacteria,” Frankel added, illustrating the practical relevance of microbiome research.
The latest studies suggest that the gut microbiome may play a pivotal role in cancer immunotherapy. By fostering specific bacterial populations, treatments could become more effective or even reduce the need for high-dose antibiotics. This approach has the potential to transform cancer care, offering a more targeted and less invasive alternative to traditional methods. As the field evolves, researchers like van den Brink and Pal are leading efforts to integrate microbiome science into mainstream oncology, aiming to reduce complications and improve survival rates.
A New Era of Cancer Treatment
The shift from broad-spectrum antibiotics to microbiome-focused therapies reflects a broader trend in personalized medicine. Scientists are now exploring how individual differences in gut bacteria might influence treatment responses, potentially allowing for tailored interventions. For example, CBM588’s use in kidney cancer trials could pave the way for similar probiotics in other cancers, such as lung or colon cancer, where microbial interactions are also being studied.
Van den Brink emphasized that the microbiome’s potential was once overlooked, with the focus solely on eradicating harmful pathogens. “We were so focused on killing all the bad microbes that we didn’t realize the good ones were essential,” he remarked. This perspective has led to a reevaluation of treatment protocols, with researchers now seeking to preserve beneficial bacteria while targeting harmful ones. The future of cancer care, according to Pal, lies in harnessing these microbial ecosystems to strengthen the body’s defenses against disease. “The microbiome is not just a byproduct of health—it’s a dynamic partner in the fight against cancer,” he asserted.
With the first late-phase trial of CBM588 now underway, the medical community is taking a bold step toward a new era of treatment. This study, along with dozens of others, represents a growing body of evidence that the gut microbiome is a critical factor in immune function and cancer outcomes. As researchers continue to uncover the complexities of microbial interactions, the potential to improve patient survival and quality of life becomes more tangible. The journey from chemotherapy to microbiome therapy is a testament to how far the field has come—and how much further it has to go.
